{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"259","value":"927"},{"groupId":"OG001","spread":"241","value":"637"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"title":"Dose Escalation 1 - Lead in Cycle Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"151","value":"771"},{"groupId":"OG001","spread":"580","value":"792"},{"groupId":"OG002","spread":"260","value":"445"},{"groupId":"OG003","spread":"359","value":"1070"},{"groupId":"OG004","spread":"875","value":"1630"},{"groupId":"OG005","spread":"16400","value":"11200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Induction cycle Day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"The PK parameter estimates for carfilzomib were estimated from plasma concentration-time profiles using standard noncompartmental approaches over the complete sampling interval.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 in combination with R3 IV for approximately 9 weeks (1-week lead-in window, 28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG000","title":"Phase 1b: Dose Escalation 1 (20 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 27 mg/m\\^2 dose in combination with R3 IV for approximately 9 weeks (1-week lead-in window, 28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG001","title":"Phase 1b: Dose Escalation 1 (20/27 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 27 mg/m\\^2 dose in combination with VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG002","title":"Phase 1b: Dose Escalation 2 (20/27 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 36 mg/m\\^2 dose in combination with VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG003","title":"Phase 1b: Dose Escalation 2 (20/36 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 45 mg/m\\^2 dose in combination VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG004","title":"Phase 1b: Dose Escalation 2 (20/45 mg/m^2)"},{"description":"Participants with relapsed or refractory ALL received carfilzomib 20 mg/m\\^2 for the first dose, followed by the target 56 mg/m\\^2 dose in combination VXLD IV for approximately 8 weeks (28-day induction cycle, and 28-day optional consolidation cycle).","id":"OG005","title":"Phase 1b: Dose Escalation 2 (20/56 mg/m^2)"}],"paramType":"MEAN","populationDescription":"Phase 1b PK Analysis Set: All participants who received the study treatment regimen during the lead-in cycle and induction cycles, and had available data. Phase 1b Dose Escalation 2 arms did not have a 1-week lead-in cycle.","reportingStatus":"POSTED","timeFrame":"Lead-in Cycle Day 1 (7-day cycle) and Induction Cycle Day 8 (28-day cycle): pre-dose, 15 minutes (m) after the start of infusion, immediately (within 2m) before the end of infusion (EOI), EOI, 10m, 30m, 1 hour (h), 2 h, and 4h post-dose","title":"Phase 1b: Maximum Concentration (Cmax) of Carfilzomib Alone and in Combination","type":"SECONDARY","unitOfMeasure":"ng/mL"}